Supplementary Materials

Supplementary Material for:

Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib

Christopher Jedeszko, Marta Paez-Ribes, Teresa Di Desidero, Shan Man, Christina R. Lee, Ping Xu, Georg A. Bjarnason, Guido Bocci, Robert S. Kerbel*

*Corresponding author. E-mail: robert.kerbel{at}sri.utoronto.ca

Published 8 April 2015, Sci. Transl. Med. 7, 282ra50 (2015)
DOI: 10.1126/scitranslmed.3010722

This PDF file includes:

  • Materials and Methods
  • Fig. S1. SN12-PM6-1 and 786-L16 are derived from RCC cell lines and have metastatic potential.
  • Fig. S2. LDM topotecan plus pazopanib are effective in the 786-L16 model.
  • Fig. S3. Combination therapy inhibits experimental “metastases” after intravenous injection.
  • Fig. S4. MTD topotecan is effective against primary tumor and metastases.
  • References (4751)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S1. Original data (provided as a separate Excel file).

[Download Table S1]